Latest Genzyme Corporation Stories

2014-05-01 12:32:03

- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated with Lemtrada did not receive a third course of treatment in the first year of the extension - CAMBRIDGE, MA, May 1, 2014 /CNW/ - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program. In Lemtrada...

2014-03-05 12:27:25

Minerva president Rogerio Vivaldi and board chairman Marc Beer leading strategy to advance pipeline of novel therapies targeting applications in neuropsychiatry. CAMBRIDGE, Mass., March 5, 2014 /PRNewswire/ -- Minerva Neurosciences, Inc., a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced the launch of the new company web site (www.minervaneurosciences.com) following the successful transfer of the Minerva Neurosciences corporate...

2014-01-13 16:26:10

CARLSBAD, Calif., Jan. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will receive $7.5 million from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from the recently announced alliance between Genzyme and Alnylam. In addition, Isis has the potential to receive royalties on products and a portion of future milestone payments. This transaction underscores the value of Isis' innovation and the leadership role Isis has played in the field of...

2013-12-30 08:27:03

TAMPA, Fla., Dec. 30, 2013 /PRNewswire/ -- Whistleblower Law Firm, P.L. is pleased to announce that the qui tam lawsuit originally brought and filed by its managing member, Natalie Khawam, Esq., MBA, MS, in the matter of United States ex rel Fuentes et.al. v. Genzyme Corporation, No. 8:09-cv-1245-T-23-EAJ, U.S. District Court for the Middle District of Florida, was settled on December 20, 2013 for $22.28 million. "I am pleased to see the case I developed come to a successful...

2013-07-31 23:26:40

As part of the multi-year agreement Gallus will provide process and method development, scale-up, clinical supply and preparation for commercial manufacturing for an infused protein-based therapy targeting the rare disease, Niemann-Pick type B. St. Louis, Missouri (PRWEB) July 31, 2013 Gallus Biopharmaceuticals, LLC (Gallus) has signed a development and manufacturing supply agreement with Genzyme, a Sanofi Company the pioneer in the development and delivery of transformative therapies for...

Word of the Day
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.